Sanofi Withdraws Approval Application for Amlitelimab, an Atopic Dermatitis Drug Acquired from Kymab for $1.1 Billion
Complete Overhaul of Pipeline Strategy
Sanofi, France's largest pharmaceutical company, has abruptly withdrawn its application for global regulatory approval of 'Amlitelimab (KY1005),' a next-generation atopic dermatitis treatment acquired through an $1.1 billion M&A deal. This decision, made under the leadership of new CEO Belén Garijo, is the result of a regular pipeline review and is based on the internal assessment that Amlitelimab failed to demonstrate superior efficacy compared to existing standard treatments. Amlitelimab is a human monoclonal antibody targeting OX40 ligand (OX40L), an immune response regulatory protein, and was once considered a key asset to succeed Sanofi's blockbuster drug 'Dupixent (dupilumab).' However, this withdrawal has significantly impacted Sanofi's long-term portfolio diversification strategy in the immunology field.
Failure in Phase 3 Trial and Limited Differentiation
The clinical disappointment of Amlitelimab became apparent when the COAST 1 Phase 3 trial in September 2025 met its primary endpoint but failed to surpass the treatment criteria of existing drugs, raising concerns in the market. The results of the additional Phase 3 trials, SHORE and COAST 2, announced in January 2026, further added to the uncertainty. In particular, the COAST 2 trial met the U.S. regulatory criteria but failed to meet the European regulatory requirement of a composite primary endpoint, resulting in a complete failure to achieve statistical significance. Although the long-term extension trial, Estuary, showed some clinical benefit, such as sustained long-term response without relapse, Sanofi concluded that it was insufficient to provide innovative benefits to patients. Ultimately, Sanofi decided that, based on the comprehensive safety and efficacy data, further commercialization efforts would be futile and initiated the process of discontinuing clinical research.
Loss of M&A Asset Value and Leadership Change
In 2021, Sanofi acquired Kymab, a UK-based biotechnology company, for an upfront payment of approximately $1.1 billion and potential milestone payments of up to $350 million, bringing Amlitelimab into its portfolio. However, the continued clinical stagnation and loss of commercial potential of Amlitelimab led to the simultaneous resignation and dismissal of the former CEO, Paul Hudson, and the head of research and development, Houman Ashrafian. This withdrawal will directly result in an impairment loss of over $1.1 billion in acquisition costs and a significant deterioration in the return on investment (ROI). This is a clear example of the potential risks and development failure burdens associated with large-scale mergers and acquisitions (M&A) strategies undertaken by global pharmaceutical companies to diversify their pipelines.
Fierce Competition in the Atopic Dermatitis Market
The global atopic dermatitis market is a massive $15 billion market, with interleukin-4/13 (IL-4/13) inhibitors, such as Dupixent, dominating the market. New drugs, such as Ebglyss (lebrikizumab), are being launched, and Janus kinase (JAK) inhibitors, such as Rinvoq (upadacitinib), are also aggressively competing. Amlitelimab, which targets OX40L, had the advantage of a longer dosing interval (once every 12 weeks), but it did not demonstrate superior clinical improvement compared to the strong immune-suppressing efficacy of existing Dupixent. As a result, Sanofi decided to quickly reorganize its portfolio and focus its resources on other indications, such as celiac disease, which are currently in Phase 2 clinical trials, rather than spending resources on less competitive candidates.
From an investor's perspective, Sanofi's withdrawal of the approval application for Amlitelimab, a key asset acquired from Kymab for $1.1 billion, following the Phase 3 trial, represents a significant loss for its immunology portfolio diversification strategy, which aimed to prepare for the expiration of Dupixent's patent. From a researcher's perspective, the confirmation of the clinical limitations of the OX40L targeting mechanism has prompted a reassessment of the development difficulty and success potential of other candidates in the same class, such as Rocatinlimab, which is being developed by Amgen. Industry experts have realized that in the global $15.9 billion atopic dermatitis market, where strong standard treatments such as Rinvoq and Ebglyss are present, the commercialization criteria for latecomers have become extremely high. In the short term, the impairment loss of the acquired asset will increase the financial burden, but in the long term, Sanofi's R&D efficiency strategy, which involves early withdrawal of unpromising pipelines and focusing resources on other areas with a higher probability of success, such as Phase 2 celiac disease, is expected to become apparent.
Source: FierceBiotech (rss)